Thomas Helleday

35.7k total citations · 6 hit papers
264 papers, 22.1k citations indexed

About

Thomas Helleday is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Thomas Helleday has authored 264 papers receiving a total of 22.1k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Molecular Biology, 111 papers in Oncology and 48 papers in Cancer Research. Recurrent topics in Thomas Helleday's work include DNA Repair Mechanisms (163 papers), PARP inhibition in cancer therapy (58 papers) and CRISPR and Genetic Engineering (37 papers). Thomas Helleday is often cited by papers focused on DNA Repair Mechanisms (163 papers), PARP inhibition in cancer therapy (58 papers) and CRISPR and Genetic Engineering (37 papers). Thomas Helleday collaborates with scholars based in Sweden, United Kingdom and United States. Thomas Helleday's co-authors include Niklas Schultz, Eva Petermann, Helen E. Bryant, Cecilia Lundin, Mark Meuth, Suzanne Kyle, Nicola J. Curtin, Huw D. Thomas, Elena López‐Knowles and Ricky A. Sharma and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Thomas Helleday

263 papers receiving 21.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

2005 3.8k citations Niklas Schultz, Huw D. Thomas et al. profile →
DNA repair pathways as targets for cancer therapy

2008 1.3k citations Thomas Helleday, Eva Petermann et al. profile →
Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair

2010 643 citations Eva Petermann, Natalia Issaeva et al. profile →
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

2011 607 citations Thomas Helleday profile →
Mechanisms underlying mutational signatures in human cancers

2014 551 citations Thomas Helleday et al. profile →
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair

2005 512 citations Claus Storgaard Sørensen, Randi G. Syljuåsen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Helleday Sweden	68	17.8k	10.2k	4.0k	2.2k	1.6k	264	22.1k
André Nussenzweig United States	75	19.2k 1.1×	6.9k 0.7×	3.6k 0.9×	2.0k 0.9×	1.4k 0.8×	161	22.3k
Shunichi Takeda Japan	80	16.6k 0.9×	7.0k 0.7×	3.5k 0.9×	2.1k 1.0×	2.1k 1.3×	303	20.9k
Andrew L. Kung United States	81	16.6k 0.9×	6.6k 0.6×	4.6k 1.1×	1.4k 0.6×	1.4k 0.9×	285	24.2k
Christopher J. Lord United Kingdom	68	16.9k 1.0×	15.1k 1.5×	4.1k 1.0×	4.0k 1.8×	967 0.6×	192	24.5k
Nicola J. Curtin United Kingdom	62	12.0k 0.7×	10.9k 1.1×	1.9k 0.5×	1.5k 0.7×	677 0.4×	197	16.7k
Yosef Shiloh Israel	66	21.1k 1.2×	9.6k 0.9×	5.8k 1.5×	1.9k 0.9×	2.5k 1.6×	204	24.2k
Junjie Chen United States	93	26.9k 1.5×	9.8k 1.0×	6.6k 1.6×	4.0k 1.9×	4.5k 2.8×	387	32.5k
Andres J. Klein–Szanto United States	83	12.0k 0.7×	7.0k 0.7×	4.9k 1.2×	1.6k 0.7×	2.6k 1.6×	383	21.3k
Susan P. Lees‐Miller Canada	78	14.2k 0.8×	6.5k 0.6×	2.8k 0.7×	1.2k 0.5×	1.6k 1.0×	181	16.6k
Allan Balmain United States	64	12.5k 0.7×	7.8k 0.8×	4.0k 1.0×	2.3k 1.0×	2.1k 1.3×	204	18.4k

Countries citing papers authored by Thomas Helleday

Since Specialization

Citations

This map shows the geographic impact of Thomas Helleday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Helleday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Helleday more than expected).

Fields of papers citing papers by Thomas Helleday

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Helleday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Helleday. The network helps show where Thomas Helleday may publish in the future.

Co-authorship network of co-authors of Thomas Helleday

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Helleday. A scholar is included among the top collaborators of Thomas Helleday based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Helleday. Thomas Helleday is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rahman, M M, et al.. (2023). 2302P Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays. Annals of Oncology. 34. S1177–S1177. 1 indexed citations

Mobashir, Mohammad, et al.. (2022). An Approach for Systems-Level Understanding of Prostate Cancer from High-Throughput Data Integration to Pathway Modeling and Simulation. Cells. 11(24). 4121–4121. 13 indexed citations

Bivik, Cecilia, Ines Köhler, Deepti Verma, et al.. (2021). MTH1 Inhibitors for the Treatment of Psoriasis. Journal of Investigative Dermatology. 141(8). 2037–2048.e4. 15 indexed citations

Das, Ishani, Helge Gad, Lars Bräutigam, et al.. (2020). AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma. Cell Death and Differentiation. 27(7). 2081–2098. 21 indexed citations

Martínez‐Barriocanal, Águeda, José Antonio Casado, Marı́a José Ramı́rez, et al.. (2020). Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer. Clinical Cancer Research. 26(12). 3044–3057. 21 indexed citations

Jaiswal, Himjyot, Jan Benada, Erik Müllers, et al.. (2017). ATM /Wip1 activities at chromatin control Plk1 re‐activation to determine G2 checkpoint duration. The EMBO Journal. 36(14). 2161–2176. 31 indexed citations

Bräutigam, Lars, Ann‐Sofie Jemth, Helge Gad, et al.. (2016). Hypoxic Signaling and the Cellular Redox Tumor Environment Determine Sensitivity to MTH1 Inhibition. Cancer Research. 76(8). 2366–2375. 35 indexed citations

Gustafsson, Robert, Ann‐Sofie Jemth, Nina Gustafsson, et al.. (2016). Crystal Structure of the Emerging Cancer Target MTHFD2 in Complex with a Substrate-Based Inhibitor. Cancer Research. 77(4). 937–948. 71 indexed citations

Ying, Songmin, Zhihui Chen, Annette L. Medhurst, et al.. (2015). DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair. Cancer Research. 76(5). 1078–1088. 68 indexed citations

10.

Loseva, Olga, Emman Shubbar, Siamak Haghdoost, et al.. (2014). Chronic Low Dose Rate Ionizing Radiation Exposure Induces Premature Senescence in Human Fibroblasts that Correlates with Up Regulation of Proteins Involved in Protection against Oxidative Stress. Proteomes. 2(3). 341–362. 24 indexed citations

11.

Schultz, Niklas, et al.. (2013). Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer. Clinical Cancer Research. 19(6). 1547–1556. 51 indexed citations

12.

Ström, Cecilia & Thomas Helleday. (2012). Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy. SHILAP Revista de lepidopterología. 2(4). 635–649. 12 indexed citations

13.

Ying, Songmin, Freddie C. Hamdy, & Thomas Helleday. (2012). Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1. Cancer Research. 72(11). 2814–2821. 273 indexed citations

14.

Brown, Brandee, Sergey V. Ivanov, Thomas Helleday, et al.. (2012). Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival. Clinical Cancer Research. 18(5). 1257–1267. 73 indexed citations

15.

Somaiah, Navita, John Yarnold, Frances Daley, et al.. (2012). The Relationship Between Homologous Recombination Repair and the Sensitivity of Human Epidermis to the Size of Daily Doses Over a 5-Week Course of Breast Radiotherapy. Clinical Cancer Research. 18(19). 5479–5488. 24 indexed citations

16.

Wilsker, Deborah, Jon Chung, Iván Pradilla, et al.. (2011). Targeted Mutations in the ATR Pathway Define Agent-Specific Requirements for Cancer Cell Growth and Survival. Molecular Cancer Therapeutics. 11(1). 98–107. 4 indexed citations

17.

Fraser, Michael, Helen Zhao, Kaisa R. Luoto, et al.. (2011). PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy. Clinical Cancer Research. 18(4). 1015–1027. 106 indexed citations

18.

Nähse, Viola, Marie Sofie Yoo Larsen, Petra Groth, et al.. (2010). Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. The Journal of Cell Biology. 188(5). 629–638. 138 indexed citations

19.

Issaeva, Natalia, Huw D. Thomas, Janneke E. Jaspers, et al.. (2010). 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research. 70(15). 6268–6276. 80 indexed citations

20.

Higgins, Geoff S., Remko Prevo, Yin-Fai Lee, et al.. (2010). A Small Interfering RNA Screen of Genes Involved in DNA Repair Identifies Tumor-Specific Radiosensitization by POLQ Knockdown. Cancer Research. 70(7). 2984–2993. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact